Case of Adrenocortical Cancer Eleven Years After Diagnosis of Adrenocortical Adenoma



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

High-resolution imaging has increased the detection rate of adrenal gland neoplasms, necessitating changes in the management of patients with adrenal incidentalomas. Despite existing guidelines, the treatment strategy in patients with incidental adrenal gland neoplasms of <4 cm remains debatable. According to the updated EHS/ENSAT guidelines on incidentalomas (2023), benign neoplasms with ≤10 HU do not require further imaging examinations. For neoplasms of <4 cm with a native density of 11–20 HU, a follow-up examination after 12 months is recommended. This paper presents a clinical case of adrenocortical cancer with autonomous cortisol secretion, which originated from a nonfunctioning right adrenal gland neoplasm of <2 cm. The tumor was detected accidentally during abdominal and retroperitoneal ultrasound and computed tomography; however, malignant transformation did not occur until 11 years later. A comprehensive preoperative assessment, including biochemical and imaging examinations, confirmed that the patient was eligible for elective surgery. A pathological examination confirmed an oncocytic adrenocortical carcinoma (Ki-67: 40%).

About the authors

Aleksandr A. Lisitsyn

North-Western State Medical University named after I.I. Mechnikov

Author for correspondence.
Email: 9213244516@mail.ru
ORCID iD: 0000-0003-2045-0044
SPIN-code: 3237-4309

MD, Cand. Sci. (Medicine), Assistant Professor

Russian Federation, Saint Petersburg

Vyacheslav P. Zemlianoy

North-Western State Medical University named after I.I. Mechnikov

Email: zeml.spb@mail.ru
ORCID iD: 0000-0003-2329-0023
SPIN-code: 5398-3460

MD, Dr. Sci. (Medicine), Professor, Honored Doctor of the Russian Federation

Russian Federation, Saint Petersburg

Vadim I. Mazurov

North-Western State Medical University named after I.I. Mechnikov

Email: maz.nwgmu@yandex.ru
ORCID iD: 0000-0002-0797-2051
SPIN-code: 6823-5482
Scopus Author ID: 16936315400

MD, Dr. Sci. (Medicine), Professor, academician of the Russian Academy of Sciences, Honored Scientist of the Russian Federation

Russian Federation, Saint Petersburg

Ludmila I. Velikanova

North-Western State Medical University named after I.I. Mechnikov

Email: velikanova46@gmail.com
ORCID iD: 0000-0002-9352-4035
SPIN-code: 5586-4851

Dr. Sci. (Biology), Professor

Russian Federation, Saint Petersburg

Irina A. Bekhtereva

North-Western State Medical University named after I.I. Mechnikov

Email: Irina.Bekhtereva@szgmu.ru
ORCID iD: 0000-0002-5206-3367
SPIN-code: 3954-2873

MD, Dr. Sci. (Medicine), Assistant Professor

Russian Federation, Saint Petersburg

References

  1. Parry SN, Lau NS. A case of adrenal cortical carcinoma arising from a regularly monitored sub-centimetre adrenal incidentaloma. Endocrinol Diabetes Metab Case Rep. 2024;2024(1):23–0120. doi: 10.1530/EDM-23-0120 EDN: KVNBWT
  2. Thuzar M, Perry-Keene DA, d'Emden MC, Duncan EL. An adrenocortical carcinoma evolving from a small adrenal incidentaloma after years of latency. AACE Clin Case Rep. 2018;4(1):65–69. doi: 10.4158/EP171931.CR
  3. Angelousi A, Jouinot A, Bourgioti C, et al. Transformation of a Benign Adrenocortical Adenoma to a Metastatic Adrenocortical Carcinoma Is Rare But It Happens. JCEM Case Rep. 2024;2(8):luae131. doi: 10.1210/jcemcr/luae131 EDN: OFDWCJ
  4. Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023;189:G1–42. doi: 10.1093/ejendo/lvad066 EDN: EZKFAO
  5. Kohli HS, Manthri S, Jain S, et al. An Adrenocortical Carcinoma Evolving After Nine Years of Latency From a Small Adrenal Incidentaloma. Cureus. 2021;13(8):e16851. doi: 10.7759/cureus.16851
  6. Aono D, Kometani M, Asano T, et al. A case of adrenocortical carcinoma diagnosed 9 years after the discovery of adrenal incidentaloma. Endocrine Journal. 2022;69(12):1415–1421. doi: 10.1507/endocrj.ej22-0171 EDN: ZCXCYQ
  7. Vogg N, Müller T, Floren A, et al. Simplified urinary steroid profiling by LC-MS as diagnostic tool for malignancy in adrenocortical tumors. Clinica Chimica Acta. 2023;543:117301. doi: 10.1016/j.cca.2023.117301
  8. Bednarczuk T, Bolanowski M, Sworczak K, et al. Adrenal incidentaloma in adults: management recommendations by the Polish Society of Endocrinology. Endokrynol Pol. 2016;67:234–258. doi: 10.5603/EP.a2016.0039 EDN: XYVWRH
  9. Tabarin A, Bardet S, Bertherat J, et al. Exploration and management of adrenal incidentalomas. French Society of Endocrinology Consensus. Ann Endocrinol. 2008;69:487–500. doi: 10.1016/j.ando.2008.09.003
  10. Zeiger MA, Thompson GB, Duh QY, et al. The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract. 2009;15(Suppl 1):1–20. doi: 10.4158/EP.15.S1.1
  11. Elhassan YS, Alahdab F, Prete A, et al. Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess: a systematic review and meta-analysis. Ann Intern Med. 2019;171:107–116. doi: 10.7326/M18-3630
  12. Reimondo G, Muller A, Ingargiola E, et al. Is Follow-up of Adrenal Incidentalomas Always Mandatory? Endocrinol Metab. 2020;35(1):26–35. doi: 10.3803/enm.2020.35.1.26 EDN: IIGCAV
  13. Heaton JH, Wood MA, Kim AC, et al. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin. Am J Pathol. 2012;181:1017–1033. doi: 10.1016/j.ajpath.2012.05.026
  14. Bernard MH, Sidhu S, Berger N, et al. A case report in favor of a multistep adrenocortical tumorigenesis. J Clin Endocrinol Metab. 2003;88(3):998–1001. doi: 10.1210/jc.2002-021117
  15. Tang T, Zhang L, Li C, Zhou T. Gastric and adrenal metastasis from breast cancer: Case report and review of literature. Medicine. 2020;99(3):e18812. doi: 10.1097/MD.0000000000018812 EDN: JFYQYQ
  16. Sahdev A. Recommendations for the management of adrenal incidentalomas: what is pertinent for radiologists? Br J Radiol. 2017;90(1072):20160627. doi: 10.1259/bjr.20160627
  17. Hong AR, Kim JH, Park KS, et al. Optimal follow-up strategies for adrenal incidentalomas: reappraisal of the 2016 ESE-ENSAT guidelines in real clinical practice. Eur J Endocrinol. 2017;177:475–483. doi: 10.1530/EJE-17-0372
  18. Lee JM, Kim MK, Ko SH, et al. Clinical Guidelines for the Management of Adrenal Incidentaloma. Endocrinol Metab. 2017;32(2):200–218. doi: 10.3803/EnM.2017.32.2.200
  19. WHO classification of tumours of endocrine organs. Lloyd RV, Osamura RY, Klöppel G, et al., editors. In: World Health Organization Classification of Tumours. Lyon, France: International Agency for Research on Cancer (IARC); 2017. 355 p. ISBN: 9789283244936
  20. Coppola Bottazzi E, Gambardella C, Mongardini FM, et al. Prognosis of Adrenal Oncocytic Neoplasms (AONs): Literature Review of 287 Cases and Presentation of the Oldest Patient. J Clin Med. 2023;12(21):6925. doi: 10.3390/jcm12216925 EDN: ONNIVE
  21. Picut B, Dubuis JB, Demarchi MS, Fournier I. Atypical clinical presentation of oncocytic adrenocortical carcinoma with decompensated metabolic syndrome and psychotic outbreak. BMJ Case Rep. 2025;18(3):e262948. doi: 10.1136/bcr-2024-262948 EDN: SJCGRO

Supplementary files

Supplementary Files
Action
1. JATS XML

© 2025 Eco-Vector